Skip to content

Combining compensatory cognitive training and medication self-management skills training in schizophrenia: A Randomized, Single-Blind, Controlled Trial

Combining compensatory cognitive training and medication self-management skills training in schizophrenia: A Randomized, Single-Blind, Controlled Trial

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900023134
Enrollment
Unknown
Registered
2019-05-13
Start date
2017-04-01
Completion date
Unknown
Last updated
2019-05-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

schizophrenia

Interventions

control group:treatment as usual
compensatory cognitive training group:compensatory cognitive training
combined intervention group:compensatory cognitive training and medication self-management skills training sessions

Sponsors

Ningxia Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1) Between 18 and 60 years old; 2) with a confirmed diagnosis of schizophrenia on the basis of a structured clinical interview for the International Classification of Disease 10th revision (ICD-10); 3) Had received antipsychotic treatment for more than six months prior to enrollment in the study; 4) Had cognitive deficits with a Montreal Cognitive Assessment (MoCA) score of lower than 26 points; 5) Intelligence quotient (IQ) more than 70 points on Wechsler Adult Intelligence Scale (WAIS) to be capable of completing the assessments and making a decision about participating in the study; 6) Had a clinically stable state to be capable of receiving the weekly group training.

Exclusion criteria

Exclusion criteria: Potential participants were excluded from the present study if: they suffered from any organic central nervous system disorders, severe somatic disorders, mental retardation, substance-related disorders, were receiving electroconvulsive therapy within 3 months of study enrollment, were receiving other cognitive-behavioral therapies, were pregnant or lactating.

Design outcomes

Primary

MeasureTime frame
Cognitive function;

Secondary

MeasureTime frame
Medication Adherence;Psychiatric symptoms;

Countries

China

Contacts

Public ContactJuan Liu

Ningxia Medical University

ryuken0518@163.com+86 13995073111

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026